Why weight-loss drug Wegovy shows promise for heart disease
A first-of-its-kind clinical trial found that Wegovy lowered the risk of heart attack and stroke in people with heart disease and obesity.| NBC News
A first-of-its-kind clinical trial found that Wegovy lowered the risk of heart attack and stroke in people with heart disease and obesity.| NBC News
Popular diabetes and weight loss drugs may also help treat conditions including PCOS, addiction, Alzheimer’s, but the science has yet to catch up with lived experiences.| NBC News
The approval could mean more employers and insurers are persuaded to cover the popular weight loss drug.| NBC News
Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.| NBC News
This brief examines the implications of rising prescriptions for costly GLP-1 drugs for state Medicaid programs as more states consider covering the drugs for weight loss. It examines recent trends in Medicaid prescriptions and gross spending on GLP-1s, and explores the potential implications of expanding coverage obesity drugs for Medicaid programs.| KFF
KFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.| KFF
